These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27566252)

  • 41. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
    Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
    Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
    Xing D; Zheng G; Schoolmeester JK; Li Z; Pallavajjala A; Haley L; Conner MG; Vang R; Hung CF; Wu TC; Ronnett BM
    Am J Surg Pathol; 2018 Jun; 42(6):750-760. PubMed ID: 29505425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The molecular biology of epithelial ovarian cancer].
    Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
    Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.
    Capodanno A; Boldrini L; Alì G; Pelliccioni S; Mussi A; Fontanini G
    Oncol Rep; 2012 Nov; 28(5):1559-66. PubMed ID: 22949056
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
    Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
    Lee YK; Park NH; Lee H
    Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047).
    Sa JK; Kim J; Kang S; Kim SW; Song T; Shim SH; Choi MC; No JH; Song JY; Kim D; Kim YM; Kim JH; Lee JW
    Int J Cancer; 2022 Oct; 151(7):1086-1097. PubMed ID: 35666535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIK3CA mutations and copy number gains in human lung cancers.
    Yamamoto H; Shigematsu H; Nomura M; Lockwood WW; Sato M; Okumura N; Soh J; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Date H; Lam WL; Minna JD; Gazdar AF
    Cancer Res; 2008 Sep; 68(17):6913-21. PubMed ID: 18757405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple gene aberrations and breast cancer: lessons from super-responders.
    Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
    BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
    Encinas G; Maistro S; Pasini FS; Katayama ML; Brentani MM; Bock GH; Folgueira MA
    Rev Assoc Med Bras (1992); 2015; 61(5):474-83. PubMed ID: 26603012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
    Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
    Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
    Voortman J; Harada T; Chang RP; Killian JK; Suuriniemi M; Smith WI; Meltzer PS; Lucchi M; Wang Y; Giaccone G
    Curr Pharm Des; 2013; 19(5):833-40. PubMed ID: 22973954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.